Tag: DAY101 for pediatric glioma

Home / DAY101 for pediatric glioma

Categories

Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma

April 2024: The Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.). This approval is specifically for patients aged 6 months and ...
day101-for-pediatric-glioma

Scan the code